Investment Newsletters

Catalyst Pharmaceutical Partners

Catalyst: Roth Capital Expects Positive Results From Phase 3 Study Of Firdapse

In a research report issued today, Roth Capital analyst Scott Henry assigned a Buy rating on Catalyst Pharmaceutical (NASDAQ:CPRX) with a $5.00 price …

Scott Fields — September 16, 2014, 1:24 PM EDT

Roth Capital Maintains Buy On Catalyst Pharmaceutical Following Initiation Of CPP-115 Second Phase 1 Study

In a research report issued today, Roth Capital analyst Scott Henry maintained a Buy rating on Catalyst Pharmaceutical (NASDAQ:CPRX) with a $3.50 price target, …

Corey Williams — September 3, 2014, 2:14 PM EDT

« 1 2